Welcome to our dedicated page for Lifemd news (Ticker: LFMD), a resource for investors and traders seeking the latest updates and insights on Lifemd stock.
LifeMD, Inc. (LFMD) operates a leading telehealth platform connecting patients with HIPAA-compliant care solutions. This page serves as the definitive source for verified company news, providing investors and healthcare professionals with timely updates on key developments.
Access consolidated information on earnings reports, strategic partnerships, regulatory milestones, and service expansions. Our curated news collection simplifies tracking LFMD's progress in digital prescription services, remote diagnostics, and integrated telehealth solutions.
Discover updates across three core areas: financial performance announcements, operational developments in WorkSimpli software solutions, and advancements in secure patient-provider communication technologies. All content is sourced from official releases and trusted financial publications.
Bookmark this page for efficient monitoring of LifeMD's innovations in cloud-based pharmacy services, nutritional supplement offerings, and telehealth infrastructure. Return regularly to stay informed about this evolving leader in virtual healthcare delivery.
On December 23, 2021, LifeMD announced a cash dividend of $0.622483 per share for its 8.875% Series A Cumulative Perpetual Preferred Stock (LFMDP), payable on January 14, 2022. The dividend will be distributed to shareholders of record on January 4, 2022. LifeMD is a growing telehealth company providing virtual medical care across the U.S., emphasizing affordable treatment and home delivery of prescriptions.
LifeMD (NASDAQ: LFMD) will present at the Stephens Annual Investment Conference on November 29, 2021, at 9:00 AM CT / 10:00 AM ET. Management will also conduct one-on-one meetings at the event.
The conference will take place in Nashville, and details for accessing the presentation will be available via a webcast link. Interested investors can find additional information on the company's website. LifeMD is a rapidly growing telehealth company providing direct-to-patient medical care across all 50 states.
LifeMD, Inc. (NASDAQ: LFMD) reported a record revenue of $24.9 million for Q3 2021, showing a 127% increase year-over-year. The company attributes 93% of its revenue to subscriptions, up from 61% last year. Adjusted EBITDA loss improved 24% sequentially, reaching $(9.0 million), indicating ongoing enhancements in profitability. Telehealth order volume surged 153%, totaling 232,293 orders. After a recent stock offering, LifeMD is in a strong capital position to pursue further growth and aims for Adjusted EBITDA break-even by Q4 2022.
LifeMD, a telehealth company, launched its virtual care platform on November 8, 2021, aiming to provide 24/7 access to personalized healthcare across the US. The platform offers direct communication with in-house physicians, unlimited messaging, and discounted prescriptions. Initially available via invitation, public access will begin on January 1, 2022. LifeMD emphasizes addressing the shortage of primary care physicians in America, aiming to enhance healthcare accessibility and efficiency.
LifeMD, a fast-growing telehealth company, announced its participation in the Credit Suisse Virtual Annual Healthcare Conference from November 8-11, 2021. The company will present on November 11 at 10:30 am ET, providing insights into its operational strategies and growth. Investors can register for the event online. LifeMD offers cash-pay virtual medical care across all U.S. states, focusing on accessible healthcare solutions. A replay of the presentation will be available in the investor relations section of the company's website.
LifeMD, Inc. (NASDAQ: LFMD) will host a conference call on November 10, 2021, at 5:00 p.m. ET to discuss its financial results for the third quarter of fiscal 2021. The call will follow a press release with results issued beforehand. The telehealth company provides virtual medical treatments and prescription medications across the U.S. interested parties can join the call by dialing 1-877-705-6003 in the U.S. and find additional information on the company's website.
LifeMD, Inc. (NASDAQ: LFMD) has successfully closed an underwritten public offering of 1,400,000 shares of its 8.875% Series A Cumulative Perpetual Preferred Stock, with a total liquidation preference of $35 million. After offering costs, the net proceeds are estimated at $32.9 million. The funds will be allocated towards a segregated dividend account, repaying debt (approximately $10 million), and for general corporate purposes, including customer acquisition. The offering included a 30-day underwriter option for an additional 210,000 shares.
LifeMD, Inc. (NASDAQ: LFMD) has successfully closed its underwritten registered public offering of 3,833,334 shares of common stock, raising approximately $21.4 million. The offering included 500,000 shares from the underwriter’s option to purchase additional shares. The proceeds will be utilized for repaying existing indebtedness and for working capital, including patient customer acquisition and capital expenditures. B. Riley Securities acted as the sole book-running manager for this offering, which was made under an effective shelf registration statement.
LifeMD, Inc. (NASDAQ: LFMD) announced the pricing of its underwritten public offering of 1,400,000 shares of 8.875% Series A Cumulative Perpetual Preferred Stock, totaling $35 million in liquidation preference. The offering, with a 30-day option for underwriters to purchase an additional 210,000 shares, is set to close on October 4, 2021. Proceeds will fund a segregated dividend account, repay certain debts, and cover working capital, including new patient acquisition expenses. The offering is made under an effective shelf registration statement with the SEC.
LifeMD, Inc. (NASDAQ: LFMD) has priced an underwritten public offering of 3,333,334 shares of common stock at $6.00 per share, aiming for gross proceeds of about $20 million. The offering includes a 30-day option for underwriters to purchase an additional 500,000 shares. The funds will be utilized to reduce debt and support working capital, including expenses for acquiring new patients and capital expenditures. The offering is expected to close on October 4, 2021, following customary conditions.
